The phase 2a trial is currently enrolling patients; updated clinical data are expected by the end of 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to troculeucel, an ...
A simple blood test could reveal which early Alzheimer’s patients are most at risk for rapid decline. Researchers found that people with high insulin resistance—measured by the TyG index—were four ...
PMN310 is an investigational monoclonal antibody designed to selectively target soluble amyloid beta oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to PMN310 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback